API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
JADENU (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Lead Product(s): Deferasirox
Therapeutic Area: Hematology Product Name: Jadenu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oakrum Pharma, LLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
DisperSol’s active programs include, DST-0509 about to enter Phase 3 for iron overload disorder, DST-2970 in Phase 2 for refractory metastatic prostate cancer and DST-8294 for treatment of clotting disorders.
Lead Product(s): Deferasirox
Therapeutic Area: Hematology Product Name: DST-0509
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 02, 2021